Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1α

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3268-3274

  Mitra, Soumya ^a   Cassar, Scott E ^a   Niles, David J ^b   Puskas, John A ^a   Frelinger, John G ^a   Foster, Thomas H ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PHOTOFRIN; PROSTAGLANDIN E2;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; HYPOXIA; IRRADIATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONCENTRATION; OXYGENATION; PHOTODYNAMIC THERAPY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TRANSPORT KINETICS;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; DIHEMATOPORPHYRIN ETHER; DINOPROSTONE; GREEN FLUORESCENT PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OXYGEN; PHOTOCHEMOTHERAPY; TRANSFECTION;

EID: 33846225573     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0421     Document Type: Article

References (29)

1. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004;5: 497-508.
2. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
3. Fingar VH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999;79:1702-8.
4. van Gael IP, Oppelaar H, Rijken PF, et al. Vascular perfusion and hypoxic areas in RIF-1 tumors after photodynamic therapy. Br J Cancer 1996;73:2888-93.
5. Engbrecht BW, Menon C, Kachur AV, Hahn SM, Fraker DL. Photofrin- mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 1999;59:4334-42.
6. Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med 2006;38:509-15.
7. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 2006;38:500-8.
8. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006;6:535-45.
9. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126:296-303.
10. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998;77:1386-94.
11. Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluropropyl)acetamide]. Cancer Res 2000;60:2636-42.
12. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000;60:4066-9.
13. Ferrario A, Von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002;62:3956-61.
14. Semenza GL. Hypoxia-inclucible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Mad 2001;7:345-50.
15. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-46.
16. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37.
17. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002;277:50081-6.
18. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003;63:2330-4.
19. Kietzmann, T, Görlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 2005;16:474-86.
20. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia- responsive vector for tumor-specific gene therapy. Gene Ther 2000;7: 493-8.
21. Vordermark D, Shibata T, Brown JM. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophores formation. Neoplasia 2001;3:527-34.
22. Mitra S, Goren EM, Frelinger JG, Foster TH. Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo. Photochem Photobiol 2003;78:615-22.
23. Henderson BW, Donovan JM. Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res 1989;49:6896-900.
24. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004;5:437-48.
25. Yuan Y, Hilliard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-1α and von Hippel-Landau protein by direct binding to hypoxia-inducible factor-1α. J Biol Chem 2003; 278:15911-6.
26. Liu XH, Kirschenbaum A, Yao S, et al. Up-regulation of vascular endothelial cell growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999;17:687-94.
27. Zhou Q, Olivio M, Lye KYK, Moore S, Sharma A, Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 2005;56:569-77.
28. Grasselli F, Basini G, Bussolati S, Bianco F. Cobalt chloride, a hypoxia-mimicking agent, modulates redox status and functional parameters of cultured swine granulose cells. Reprod Fertil Dev 2005;17:715-20.
29. Ratcliffe PJ, Pugh CW, Maxwell PH. Targeting tumors through the HIF system. Nat Mad 2000;6:1315-6.